Investment Rating - The report assigns an "Outperform" rating for the pharmaceutical sector, indicating a positive outlook compared to the broader market [4][11]. Core Insights - The pharmaceutical sector is experiencing a significant transformation, with the government designating biopharmaceuticals as a "new pillar industry," signaling a strategic elevation in its importance [5]. - The report highlights the successful approval of the world's first photodynamic therapy product for cervical precancerous lesions in China, showcasing innovation in non-invasive treatments [5]. - Despite recent market volatility due to geopolitical tensions, the long-term trend of innovation in China's pharmaceutical industry remains strong, with expectations for continued growth in overseas markets for innovative drugs [5][4]. Summary by Sections Industry Performance - The SW Pharmaceutical Bio Index decreased by 2.78% during the week of March 2 to March 8, underperforming the CSI 300 Index, which fell by 1.07% [4]. - Among sub-sectors, only in vitro diagnostics showed a slight gain of 0.18%, while CXO and medical devices experienced declines of 4.99% and 4.62%, respectively [4]. Government Policy and Market Trends - The Chinese government has consistently included "innovative drugs" in its work reports for three consecutive years, emphasizing support for the development of innovative pharmaceuticals and medical devices [5]. - In 2025, the total number of License-out transactions for Chinese innovative drugs reached 157, with a total value of approximately $135.7 billion, indicating a doubling in upfront payments compared to 2024 [5]. Investment Opportunities - The report suggests focusing on investment opportunities in ADCs, bispecific antibodies, small nucleic acids, and weight-loss drugs, as well as high-growth areas like CXO, medical device exports, brain-computer interfaces, and AI in healthcare [5].
医药行业跟踪报告：生物医药首次被列为国家“新兴支柱产业”，战略定位进一步提升
Shanghai Aijian Securities·2026-03-10 08:15